This is an old revision of this page, as edited by BogBot (talk | contribs) at 19:49, 2 September 2011 (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 19:49, 2 September 2011 by BogBot (talk | contribs) (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.157.907  |
| Chemical and physical data | |
| Formula | C18H14F3N3O6S |
| Molar mass | 457.380 g/mol g·mol |
| (verify) | |
Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats and dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.
See also
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |
 | This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it. |